

A nature-inspired design yields a new class of steroids against tripanosomatids.

Elena Aguilera^{1#}, Cintya Perdomo^{2#}, Alejandra Espindola², Ileana Corvo², Paula Faral-Tello³, Carlos Robello^{3,4}, Elva Serna⁵, Fátima Benítez^{5,6}, Rocío Riveros^{5,6}, Susana Torres⁵, Ninfa I. Vera de Bilbao⁵, Gloria Yaluff^{5*}, Guzmán Alvarez^{2*}

- ¹ Grupo de Química Medicinal-Laboratorio de Química Orgánica, Facultad de Ciencias, Universidad de la República, Montevideo, C.P. 11400, Uruguay; elepao168@gmail.com (E.A.).
 - ² Laboratorio de Moléculas Bioactivas, CENUR Litoral Norte, Universidad de la República, Ruta 3 (km 363), Paysandú, C.P. 60000, Uruguay; cuquis266@gmail.com (C.P.), ale.espindola1991@gmail.com (A.E.), ilecorvo@gmail.com (I.C.), guzmanalvarezlqo@gmail.com (G.A.).
 - ³ Unidad de Biología Molecular, Institut Pasteur de Montevideo, Montevideo, C.P. 11400, Uruguay; pfaral@pasteur.edu.uy (P.F-T), robello@pasteur.edu.uy (C.R.).
 - ⁴ Departamento de Bioquímica, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay
 - ⁵ Departamento de Medicina Tropical, Instituto de Investigaciones en Ciencias de la Salud, Universidad Nacional de Asunción, San Lorenzo, C.P. 2169., Paraguay; elvsern@gmail.com (E.S.), susitorres1@hotmail.com (S.T.), nverabilbao@gmail.com (N. I. V. de B.), gloriayaluff@yahoo.com (G.Y.).
 - ⁶ Facultad de Ciencias Exactas y Naturales, Universidad Nacional de Asunción, San Lorenzo, C.P. 2169., Paraguay; fatimaapodaca14@gmail.com (F.B.), r.riverosmaidana@gmail.com (R.R.).
- # Both authors contribute equally to this work.
* Correspondence: GY: gloriayaluff@yahoo.com, GA: guzmanalvarezlqo@gmail.com; Tel.: +59899274984

Table 1S. Total data from the in vitro assays with the parasites for 20 compounds

STRUCTURE	IDENTIFIER	IC ₅₀ ± %SD (μM) epimastigotes <i>T. cruzi</i>	IC ₅₀ ± %SD (μM) promastigotes <i>L. braziliensis</i> / <i>L. amazonensis</i>	IC ₅₀ ± %SD (μM) promastigotes <i>L. infantum</i>	IC ₅₀ ± %SD (μM) promastigotes <i>L. infantum</i> uy* ^{p/c}
	Nifurtimox®	7±2	nd	6±2	10±2 ^c
	Glucantime®	nd	18±2	20±9	nd
	Miltefosine®	8±2	nd	0.9±0.2	5±2
	1054	>25	>25	>25	>25
	1319	>25	>25	>25	>25
	1257	>25	>25	>25	>25
	1259	12±3	23±5	>25	>25
	1256	>25	>25	>25	>25
	1417	20±5	>25	>25	>25
	1262	>25	>25	>25	>25
	1288	>25	>25	>25	>25
	1279	>25	>25	>25	>25
	1289	>25	>25	>25	>25
	1287	>25	23±3	>25	>25
	1272	>25	16±3	>25	>25











	1125	>25	<20	>25	25/>25
	1260	1.2	<22	0.2±0.1	0.2
	1154	7,8	nd	>25	>25
	1291	25	nd	>25	>25
	1087	>25	>25	>25	nd
	1144	>25	>25	>25	nd
	1261	>25	>25	>25	>25
	1263	8	>25	>25	>25
	1317	>25	>25	>25	>25

Figure 1S. Pharmacokinetic r profiles data output from SwissADME.

A) Glucantime



B) Compound 1260




Figure 2S. TLC from the hepatic metabolic stability assay in vitro. FM (Microsomal fraction) FC (cytosolic Fraction).

